Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses (original) (raw)

• van den Eynde, B. J. & van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol. 9, 684–693 (1997).
  CAS PubMed Google Scholar
• Mitchell, M. S. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin. Oncol. 25, 623–635 (1998).
  CAS PubMed Google Scholar
• Hsueh, E. C. et al. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 85, 2160–2169 (1999).
  CAS PubMed Google Scholar
• Musselli, C., Livingston, P. O. & Ragupathi, G. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan–Kettering experience. J. Cancer Res. Clin. Oncol. 127 (Suppl. 2), R20–R26 (2001).
  CAS PubMed Google Scholar
• Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539–3543 (1993).
  CAS PubMed PubMed Central Google Scholar
• Sampson, J. H. et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system. Proc. Natl Acad. Sci. USA 93, 10399–10404 (1996).
  CAS PubMed PubMed Central Google Scholar
• Simons, J. W. et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte–macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537–1546 (1997).
  CAS PubMed PubMed Central Google Scholar
• Tuting, T. et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the TH1-biasing cytokines IL-12 and IFN-α. J. Immunol. 160, 1139–1147 (1998).
  CAS PubMed Google Scholar
• Kwak, L. W. et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209–1215 (1992).
  CAS PubMed Google Scholar
• Boczkowski, D., Nair, S. K., Snyder, D. & Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465–472 (1996).
  CAS PubMed Google Scholar
• Larregina, A. T. et al. Direct transfection and activation of human cutaneous dendritic cells. Gene Ther. 8, 608–617 (2001).
  CAS PubMed Google Scholar
• Reichardt, V. L. et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood 93, 2411–2419 (1999).
  CAS PubMed Google Scholar
• Reddy, S. A., Okada, C., Wong, C., Bahler, D. & Levy, R. T cell antigen receptor vaccines for active therapy of T cell malignancies. Ann. NY Acad. Sci. 941, 97–105 (2001).
  CAS PubMed Google Scholar
• Nestle, F. O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328–332 (1998).
  CAS PubMed Google Scholar
• Fong, L. et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sci. USA 98, 8809–8814 (2001).In a clinical trial using dendritic cells pulsed with an altered peptide ligand of CEA to vaccinate patients with colon cancer, the authors show, using tetramer analysis, that expansion of CEA-specific T cells in vivo correlated with clinical responses.
  CAS PubMed PubMed Central Google Scholar
• Thurner, B. et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669–1678 (1999).Regression of individual lesions were observed in 6 out of 11 patients with advanced melanoma receiving a MAGE3-pulsed dendritic-cell vaccine. Antigen-loss variants were identified in residual tumour of some patients.
  CAS PubMed PubMed Central Google Scholar
• Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318–1321 (1986).
  CAS PubMed Google Scholar
• Riddell, S. R. et al. Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum. Gene Ther. 3, 319–338 (1992).
  CAS PubMed Google Scholar
• Yee, C. et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192, 1637–1644 (2000).In a patient receiving adoptive therapy with T-cell clones targeting MART1, transferred T cells were tracked with peptide–MHC tetramers and shown to migrate to antigen-positive sites of skin and tumour and to mediate an antigen-specific immune response.
  CAS PubMed PubMed Central Google Scholar
• Yee, C., Riddell, S. R. & Greenberg, P. D. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9, 702–708 (1997).
  CAS PubMed Google Scholar
• Yee, C., Savage, P. A., Lee, P. P., Davis, M. M. & Greenberg, P. D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide–MHC tetramers. J. Immunol. 162, 2227–2234 (1999).Peptide–MHC tetramers were used to define the TCR affinity of antigen-specific T cells (see also reference 87).
  CAS PubMed Google Scholar
• Simon, R. M. et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol. 19, 1848–1854 (2001).
  CAS PubMed Google Scholar
• Disis, M. L. et al. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 6, 1347–1350 (2000).
  CAS PubMed Google Scholar
• Habal, N. et al. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann. Surg. Oncol. 8, 389–401 (2001).
  CAS PubMed Google Scholar
• Hsueh, E. C., Gupta, R. K., Qi, K. & Morton, D. L. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J. Clin. Oncol. 16, 2913–2920 (1998).
  CAS PubMed Google Scholar
• Lee, P. et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19, 3836–3847 (2001).
  CAS PubMed Google Scholar
• Hsu, F. J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52–58 (1996).
  CAS PubMed Google Scholar
• Bendandi, M. et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma. Nature Med. 5, 1171–1177 (1999).
  CAS PubMed Google Scholar
• Marchand, M. et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE3. Int. J. Cancer 63, 883–885 (1995).
  CAS PubMed Google Scholar
• Marchand, M. et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80, 219–230 (1999).
  CAS PubMed Google Scholar
• Mukherji, B. et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl Acad. Sci. USA 92, 8078–8082 (1995).
  CAS PubMed PubMed Central Google Scholar
• Cormier, J. N. et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from Mart1/Melan A. Cancer J. Sci. Am. 3, 37–44 (1997).
  CAS PubMed PubMed Central Google Scholar
• Rosenberg, S. A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321–327 (1998).
  CAS PubMed Google Scholar
• Jager, E. et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl Acad. Sci. USA 97, 4760–4765 (2000).References 26–34 describe some of the clinical trials that involve augmentation of an antigen-specific T-cell response.
  CAS PubMed PubMed Central Google Scholar
• Altman, J. D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94–96 (1996).
  CAS PubMed Google Scholar
• Davis, M. M. et al. T cell receptor biochemistry, repertoire selection and general features of TCR and Ig structure. Ciba Found. Symp. 204, 94–100; discussion 100–104 (1997).
  CAS PubMed Google Scholar
• Schneck, J. P. Monitoring antigen-specific T cells using MHC–Ig dimers. Immunol. Invest. 29, 163–169 (2000).
  CAS PubMed Google Scholar
• Yee, C., Davis, M. M. & Lee, P. P. The Use of Peptide–MHC Tetramers in T-Cell Therapy of Melanoma (Academic Press, San Diego, 2000).
  Google Scholar
• Lee, P. P. et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Med. 5, 677–685 (1999).Multiparametric analysis of endogenous populations of circulating tumour-specific T cells revealed an activational defect in T cells that recognize melanoma-associated differentiation antigens.
  CAS PubMed Google Scholar
• Callan, M. F. et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein–Barr virus in vivo. J. Exp. Med. 187, 1395–1402 (1998).
  CAS PubMed PubMed Central Google Scholar
• Haanen, J. et al. In situ detection of virus- and tumor-specific T-cell immunity. Nature Med. 6, 1056–1060 (2000).
  CAS PubMed Google Scholar
• Lee, K. H. et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J. Immunol. 161, 4183–4194 (1998).
  CAS PubMed Google Scholar
• Pongers-Willemse, M. J. et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 12, 2006–2014 (1998).
  CAS PubMed Google Scholar
• Coulie, P. G. et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl Acad. Sci. USA 98, 10290–10295 (2001).
  CAS PubMed PubMed Central Google Scholar
• Riddell, S. R. et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med. 2, 216–223 (1996).
  CAS PubMed Google Scholar
• Thomis, D. C. et al. A FAS-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97, 1249–1257 (2001).
  CAS PubMed Google Scholar
• Brodie, S. J. et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nature Med. 5, 34–41 (1999).In situ localization of gene-marked T-cell clones in situ following adoptive T-cell therapy.
  CAS PubMed Google Scholar
• Lamana, M. L., Segovia, J. C., Guenechea, G. & Bueren, J. A. Systematic analysis of clinically applicable conditions leading to a high efficiency of transduction and transgene expression in human T cells. J. Gene Med. 3, 32–41 (2001).
  CAS PubMed Google Scholar
• Kammula, U. S. et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol. 163, 6867–6875 (1999).Application of real-time PCR analysis of cytokine expression to evaluate antigen-specific T-cell response to vaccination.
  CAS PubMed Google Scholar
• Mocellin, S., Ohnmacht, G. A., Wang, E. & Marincola, F. M. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int. J. Cancer 93, 236–242 (2001).
  CAS PubMed Google Scholar
• Pala, P., Hussell, T. & Openshaw, P. J. M. Flow cytometric measurement of intracellular cytokines. J. Immunol. Methods 243, 107–124 (2000).
  CAS PubMed Google Scholar
• Murali-Krishna, K. et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8, 177–187 (1998).
  CAS PubMed Google Scholar
• Becker, C. et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nature Med. 7, 1159–1162 (2001).
  CAS PubMed Google Scholar
• Herr, W., Schneider, J., Lohse, A. W., Meyer zum Buschenfelde, K. H. & Wolfel, T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor-α in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods 191, 131–142 (1996).
  CAS PubMed Google Scholar
• Gnjatic, S. et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl Acad. Sci. USA 97, 10917–10922 (2000).
  CAS PubMed PubMed Central Google Scholar
• Herr, W. et al. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor-α spots in response to peptide antigens. J. Immunol. Methods 203, 141–152 (1997).
  CAS PubMed Google Scholar
• Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205–2213 (1998).
  CAS PubMed PubMed Central Google Scholar
• Taswell, C. Limiting dilution assays for the determination of immunocompetent cell frequencies. III. Validity tests for the single-hit Poisson model. J. Immunol. Methods 72, 29–40 (1984).
  CAS PubMed Google Scholar
• Jager, E. et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl Acad. Sci. USA 97, 12198–12203 (2000).Stabilization and regression of individual metastases in some patients with melanoma, receiving a peptide vaccine that targets NY-ESO-1, provide evidence of clinical correlation with ELISPOT analyses.
  CAS PubMed PubMed Central Google Scholar
• Molldrem, J. J. et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Med. 6, 1018–1023 (2000).
  CAS PubMed Google Scholar
• Lee, K. H. et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163, 6292–6300 (1999).
  CAS PubMed Google Scholar
• Fong, L. et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol. 167, 7150–7156 (2001).
  CAS PubMed Google Scholar
• Cheever, M. A., Thompson, D. B., Klarnet, J. P. & Greenberg, P. D. Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J. Exp. Med. 163, 1100–1112 (1986).
  CAS PubMed Google Scholar
• Ohlen, C., Kalos, M., Hong, D. J., Shur, A. C. & Greenberg, P. D. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol. 166, 2863–2870 (2001).
  CAS PubMed Google Scholar
• Ochsenbein, A. F. et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl Acad. Sci. USA 96, 2233–2238 (1999).
  CAS PubMed PubMed Central Google Scholar
• Mihm, M. C. Jr, Clemente, C. G. & Cascinelli, N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 74, 43–47 (1996).
  PubMed Google Scholar
• Underwood, J. C. Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br. J. Cancer 30, 538–548 (1974).
  CAS PubMed PubMed Central Google Scholar
• Watt, A. G. & House, A. K. Colonic carcinoma: a quantitative assessment of lymphocyte infiltration at the periphery of colonic tumors related to prognosis. Cancer 41, 279–282 (1978).
  CAS PubMed Google Scholar
• van Nagell, J. R. Jr, Donaldson, E. S., Wood, E. G. & Parker, J. C. Jr. The significance of vascular invasion and lymphocytic infiltration in invasive cervical cancer. Cancer 41, 228–234 (1978).
  PubMed Google Scholar
• Hanson, H. L. et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13, 265–276 (2000).
  CAS PubMed Google Scholar
• Speiser, D. E. & Ohashi, P. S. Activation of cytotoxic T cells by solid tumours? Cell. Mol. Life Sci. 54, 263–271 (1998).
  CAS PubMed Google Scholar
• Ochsenbein, A. F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058–1064 (2001).
  CAS PubMed Google Scholar
• Hardy, J. et al. Bioluminescence imaging of lymphocyte trafficking in vivo. Exp. Hematol. 29, 1353–1360 (2001).
  CAS PubMed Google Scholar
• Mizoguchi, H. et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258, 1795–1798 (1992).
  CAS PubMed Google Scholar
• Correa, M. R. et al. Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J. Immunol. 158, 5292–5296 (1997).
  CAS PubMed Google Scholar
• Moser, J. M., Gibbs, J., Jensen, P. E. & Lukacher, A. E. CD94-NKG2A receptors regulate antiviral CD8+ T cell responses. Nature Immunol. 3, 189–195 (2002).
  CAS Google Scholar
• Deeths, M. J., Kedl, R. M. & Mescher, M. F. CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J. Immunol. 163, 102–110 (1999).
  CAS PubMed Google Scholar
• Staveley-O'Carroll, K. et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl Acad. Sci. USA 95, 1178–1183 (1998).
  CAS PubMed PubMed Central Google Scholar
• Torre-Amione, G. et al. A highly immunogenic tumor transfected with a murine transforming growth factor type-β1 cDNA escapes immune surveillance. Proc. Natl Acad. Sci. USA 87, 1486–1490 (1990).
  CAS PubMed PubMed Central Google Scholar
• Novak, E. J., Liu, A. W., Nepom, G. T. & Kwok, W. W. MHC class II tetramers identify peptide-specific human CD4+ T cells proliferating in response to influenza A antigen. J. Clin. Invest. 104, R63–R67 (1999).Authors develop peptide–MHC class II tetramers that recognize human antigen-specific CD4+ T cells.
• Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J. & Kast, W. M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl Acad. Sci. USA 93, 7855–7860 (1996).
  CAS PubMed PubMed Central Google Scholar
• Alexander-Miller, M. A., Leggatt, G. R. & Berzofsky, J. A. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl Acad. Sci. USA 93, 4102–4107 (1996).
  CAS PubMed PubMed Central Google Scholar
• Gervois, N., Guilloux, Y., Diez, E. & Jotereau, F. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC–tumor peptide interactions. J. Exp. Med. 183, 2403–2407 (1996).
  CAS PubMed Google Scholar
• Crawford, F., Kozono, H., White, J., Marrack, P. & Kappler, J. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 8, 675–682 (1998).
  CAS PubMed Google Scholar
• Savage, P. A., Boniface, J. J. & Davis, M. M. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 10, 485–492 (1999).
  CAS PubMed Google Scholar
• Noppen, C., Spagnoli, G. C. & Schaefer, C. Isolation of multiple mRNAs from a few eukaryotic cells: a fast method to obtain templates for RT-PCR. Biotechniques 21, 394–396 (1996).
  CAS PubMed Google Scholar
• Dutoit, V. et al. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J. Immunol. 168, 1167–1171 (2002).Peptide–MHC tetramers were used to define the TCR affinity of antigen-specific T cells (see also reference 21).
  CAS PubMed Google Scholar
• Kessels, H. W., Wolkers, M. C., van den Boom, M. D., van der Valk, M. A. & Schumacher, T. N. Immunotherapy through TCR gene transfer. Nature Immunol. 2, 957–961 (2001).Designing T cells with a given antigen specificity by the transfer of genes that encode the TCR.
  CAS Google Scholar
• Urban, J. L., Holland, J. M., Kripke, M. L. & Schreider, H. Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation. J. Exp. Med. 156, 1025–1041 (1982).
  CAS PubMed Google Scholar
• Saleh, F. H., Crotty, K. A., Hersey, P. & Menzies, S. W. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen Melan-A/ MART-1. Int. J. Cancer 94, 551–557 (2001).
  CAS PubMed Google Scholar
• Shankaran, V. et al. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001).Endogenous immunoselection of tumour cells can lead to the appearance of antigen-loss tumour variants that escape immune detection in the immunocompetent host.
  CAS PubMed Google Scholar
• Panelli, M. C. et al. Expansion of tumor–T cell pairs from fine needle aspirates of melanoma metastases. J. Immunol. 164, 495–504 (2000).
  CAS PubMed Google Scholar
• Vitale, M. et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 58, 737–742 (1998).
  CAS PubMed Google Scholar
• Ferrone, S. & Marincola, F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16, 487–494 (1995).
  CAS PubMed Google Scholar
• Hicklin, D. J., Kageshita, T. & Ferrone, S. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. Tissue Antigens 48, 38–46 (1996).
  CAS PubMed Google Scholar
• Wang, Z., Margulies, L., Hicklin, D. J. & Ferrone, S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Tissue Antigens 47, 382–390 (1996).
  CAS PubMed Google Scholar
• Yang, G., Hellstrom, K. E., Mizuno, M. T. & Chen, L. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7–CD28 costimulation. J. Immunol. 155, 3897–3903 (1995).
  CAS PubMed Google Scholar
• Beck, C., Schreiber, H. & Rowley, D. Role of TGF-β in immune-evasion of cancer. Microsc. Res. Tech. 52, 387–395 (2001).
  CAS PubMed Google Scholar
• Barth, R. J. Jr, Camp, B. J., Martuscello, T. A., Dain, B. J. & Memoli, V.A. The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-α and interleukin-4 predicts improved survival. Cancer 78, 1168–1178 (1996).
  PubMed Google Scholar
• Zea, A. H. et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1, 1327–1335 (1995).
  CAS PubMed Google Scholar
• Maccalli, C. et al. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. J. Immunol. 163, 6912–6923 (1999).
  CAS PubMed Google Scholar
• Bladergroen, B. A. et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 99, 232–237 (2002).
  CAS PubMed Google Scholar
• Medema, J. P., de Jong, J., van Hall, T., Melief, C. J. & Offringa, R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190, 1033–1038 (1999).
  CAS PubMed PubMed Central Google Scholar
• Ambrosini, G., Adida, C. & Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3, 917–921 (1997).
  CAS PubMed Google Scholar
• Nakashima, M., Sonoda, K. & Watanabe, T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nature Med. 5, 938–942 (1999).
  CAS PubMed Google Scholar
• Mellado, M., de Ana, A. M., Moreno, M. C., Martinez, C. & Rodriguez-Frade, J. M. A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Curr. Biol. 11, 691–696 (2001).
  CAS PubMed Google Scholar
• Riker, A. I. et al. Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma. Cancer Detect. Prev. 23, 387–396 (1999).References 93–107 describe mechanisms of tumour immune escape through defects in antigen expression or antigen presentation (references 93–96 ), the presence of an immune-suppressive tumour microenvironment (references 97–101 ) and tumour upregulation of immunoprotective mechanisms (references 101–107).
  CAS PubMed Google Scholar